FY2026 EPS Estimates for BioCardia Reduced by HC Wainwright

BioCardia, Inc. (NASDAQ:BCDA) – Equities researchers at HC Wainwright cut their FY2026 earnings per share estimates for shares of BioCardia in a report released on Thursday, March 26th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.71) per share for the year, down from their prior estimate of ($0.69). The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, BioCardia presently has an average rating of “Hold” and a consensus target price of $25.00.

BioCardia Price Performance

NASDAQ BCDA opened at $1.16 on Monday. BioCardia has a twelve month low of $1.00 and a twelve month high of $3.20. The business has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.32. The firm has a market cap of $12.69 million, a price-to-earnings ratio of -0.90 and a beta of 0.60.

Institutional Trading of BioCardia

A number of institutional investors and hedge funds have recently bought and sold shares of BCDA. DRW Securities LLC purchased a new stake in BioCardia in the 4th quarter worth $72,000. Geode Capital Management LLC grew its position in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in shares of BioCardia during the second quarter valued at about $40,000. 20.57% of the stock is currently owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.